Table 2.
Frequency (%) of erythrocytic nuclear abnormalities (ENAs) of Oreochromis niloticus exposed to fluoxetine for 96 h.
Frequency (%) of ENAs | Treatment groups |
|||||
---|---|---|---|---|---|---|
NC | SC | 10 µg/L | 100 µg/L | 1000 µg/L | PC | |
MN | 0.04 ± 0.04 | 0.06 ± 0.03 | 0.07 ± 0.04 | 0.24 ± 0.11* | 0.26 ± 0.11* | 0.56 ± 0.32* |
LN | 0.05 ± 0.04 | 0.05 ± 0.04 | 0.06 ± 0.05 | 0.07 ± 0.04 | 0.14 ± 0.08* | 0.17 ± 0.08* |
BN | 0.15 ± 0.06 | 0.15 ± 0.06 | 0.16 ± 0.06 | 0.20 ± 0.07 | 0.25 ± 0.14 | 0.72 ± 0.29* |
NN | 0.20 ± 0.07 | 0.20 ± 0.06 | 0.21 ± 0.07 | 0.26 ± 0.07 | 0.37 ± 0.14* | 0.84 ± 0.35* |
KN | 0.33 ± 0.15 | 0.34 ± 0.14 | 0.36 ± 0.16 | 0.41 ± 0.15 | 0.60 ± 0.16* | 0.95 ± 0.24* |
BC | 0.01 ± 0.02 | 0.01 ± 0.02 | 0.01 ± 0.02 | 0.01 ± 0.02 | 0.01 ± 0.02 | 0.03 ± 0.05 |
Total ENAs | 0.76 ± 0.20 | 0.79 ± 0.23 | 0.86 ± 0.27 | 1.18 ± 0.20* | 1.62 ± 0.48* | 3.26 ± 0.64* |
The results expressed as mean ± standard deviation. * Statistically significant differences to the negative control group (p < 0.05). NC: negative control group; SC: solvent control group; PC: positive control group; 10, 100, 1000: treatment groups exposed to 10 µg/L, 100 µg/L and 1000 µg/L of FLX, respectively; MN: micronucleus; LN: lobed nucleus; BN: blebbed nucleus; NN: notched nucleus; BC: binucleated cell; KN: kidney-shaped nucleus.